Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jenscare Scientific Co. Ltd. Class H ( (HK:9877) ) has issued an announcement.
Jenscare Scientific Co., Ltd. announced remarkable results from its multi-product portfolio at the TCT 2025 conference in San Francisco. The LuX-Valve Plus TRINITY study showed a 97% device success rate and significant improvements in patients’ cardiac function and quality of life. The JensClip and Ken-Valve studies also demonstrated promising outcomes, positioning Jenscare as a leader in transcatheter heart valve therapies and potentially impacting its market presence positively.
More about Jenscare Scientific Co. Ltd. Class H
Jenscare Scientific Co., Ltd. is a company based in the People’s Republic of China, specializing in medical technology. It focuses on developing innovative transcatheter heart valve therapies, targeting conditions such as tricuspid regurgitation and mitral valve issues, with a market focus on high-risk surgical patients.
Average Trading Volume: 683,868
Technical Sentiment Signal: Hold
Current Market Cap: HK$6.1B
Learn more about 9877 stock on TipRanks’ Stock Analysis page.